APR 2 1 2003

K030782/,

# 510(k) SUMMARY OF SUBSTANTIAL EQUIVALENCE

Proprietary Name:

SEAMGUARD® Bioabsorbable Staple Line

Reinforcement Material

Common Name:

Staple Line Reinforcement Material

Classification Name:

Surgical Mesh

Device Classification:

Class II

Product Classification and Code:

878.3300, FTL

Classification Panel:

General and Plastic Surgery Devices

Establishment Registration Number: 2025240

Contact Person:

Mike Johnson

Regulatory Affairs

Medical Products Division WL Gore & Associates, Inc. 3450 West Kiltie Lane Flagstaff, AZ 86002-0500

Telephone: (928) 864-3615 Facsimile: (928) 864-4144 E-mail: mdjohnso@wlgore.com

#### **Performance Standards**

Performance standards do not currently exist for these devices. None established under Section 514.

#### **Device Description**

The SEAMGUARD Bioabsorbable Staple Line Reinforcement Material consists of a bioabsorbable membrane formed into a sleeve with use of a polyester braided suture pullcord. The bioabsorbable material is comprised of a microporous structure of synthetic



510(k) Premarket Notification 510(k) Summary of Substantial Equivalence K030782/2

SEAMGUARD® Bioabsorbable Staple Line Reinforcement Material

bioabsorbable glycolide and trimethylene carbonate copolymer. The SEAMGUARD Bioabsorbable Staple Line Reinforcement Material is to be used with surgical stapling devices.

The SEAMGUARD Bioabsorbable Staple Line Reinforcement Material is supplied in sterile, foil film laminate pouches. Pouches contain the necessary material for the cartridge jaw and the anvil jaw of the surgical stapler. Tyvek<sup>®</sup> inserts facilitate placement of the reinforcement material onto the stapler jaws.

#### Indication for Use

SEAMGUARD Bioabsorbable Staple Line Reinforcement Material is indicated for surgical procedures in which soft tissue transection or resection with staple line reinforcement is needed. SEAMGUARD Bioabsorbable Staple Line Reinforcement Material can be used for reinforcement of staple lines during lung resection and for reinforcement of gastric staple lines during bariatric surgical procedures of gastric bypass and gastric banding.

#### **Substantially Equivalent Devices**

In WL Gore & Associates' opinion, the SEAMGUARD Bioabsorbable Staple Line Reinforcement Material is believed to be substantially equivalent to the following predicate devices currently in interstate commerce with respect to comparable features, materials of construction and intended use.

- SEAMGUARD<sup>®</sup> Staple Line Reinforcement Material (WL Gore & Associates, Inc., Flagstaff, AZ) K001789
- Absorbable Foam Buttress (AFB) (J&J Corporate Biomaterials Center, a Division of Ethicon, Somerville, NJ) – K014183
- Resolut ADAPT® ST Regenerative Membrane (WL Gore & Associates, Inc., Flagstaff, AZ) – K013346
- Polyviolene® Braided Polyester Suture (Look, Inc., Ada, OK) K926167

Labeling, packaging and sterilization of the SEAMGUARD Bioabsorbable Staple Line Reinforcement Material is substantially equivalent to that of the predicate devices listed above.

### **Summary of Studies**

WL Gore & Associates, Inc. performed device integrity testing to support that the SEAMGUARD Bioabsorbable Staple Line Reinforcement Material is equivalent to the predicate devices. All device integrity test results for the SEAMGUARD Bioabsorbable Staple Line Reinforcement Material met specified requirements.





APR 2 1 2003

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Mr. Mike Johnson Regulatory Affairs W.L. Gore & Associates, Inc. 3450 West Kiltie Lane Flagstaff, Arizona 86002-0500

Re: K030782

Trade/Device Name: SEAMGUARD® Bioabsorbable Staple Line Reinforcement Material

Regulation Number: 21 CFR 878.3300 Regulation Name: Surgical Mesh

Regulatory Class: II Product Code: FTM Dated: March 10, 2003 Received: March 11, 2003

#### Dear Mr. Johnson:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4659. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97) you may obtain. Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,

For Celia M. Witten, Ph.D., M.D.

Director

Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health

Miriam C Provost

Enclosure

K 630782

## INDICATION FOR USE

510(k) Number (if known): K030762

	·	
Device Name:	SEAMGUARD' Material	<sup>®</sup> Bioabsorbable Staple Line Reinforcement
Intended Use / Indication For Use:	Material is indic tissue transectio reinforcement is Staple Line Rein reinforcement of reinforcement of	Bioabsorbable Staple Line Reinforcement cated for surgical procedures in which soft in or resection with staple line aneeded. SEAMGUARD Bioabsorbable inforcement Material can be used for a staple lines during lung resection and for a f gastric staple lines during bariatric ires of gastric bypass and gastric banding.
and N	rum C. Proposition Sign-Off) ion of General, Neurological Decay Number	vices
(PLEASE DO NOT WRITE RELOY	WTHISTINE CON	NTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of		
		(322)
Prescription Use	OR	Over-The-Counter Use
(Per 21 CFR 801,109)	OK	(Optional Format 1-2-96)
		(0)